<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159352</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-093</org_study_id>
    <nct_id>NCT02159352</nct_id>
  </id_info>
  <brief_title>Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants</brief_title>
  <official_title>A Phase 1 Clinical Study to Assess the Effect of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether multiple doses of darunavir/ritonavir or
      lopinavir/ritonavir affect the pharmacokinetics of daclatasvir in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax was obtained from concentration-time plot using a noncompartmental method and a validated pharmacokinetic analysis program.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC(TAU) was the area under the curve from time zero to end of dosing interval. AUC(TAU) was obtained from concentration-time plot of daclatasvir using noncompartmental method and a validated pharmacokinetic analysis program.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax was obtained from concentration-time plot of daclatasvir by using non-compartmental method by a validated pharmacokinetic analysis program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>C24 was obtained from concentration time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized Maximum Observed Plasma Concentration (Cmax/D) and Dose-normalized Plasma Concentration Observed at 24 Hours Postdose (C24/D) of Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax/D and C24/D are obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC(TAU)/D was obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge for AEs (up to 15 days); Day 1 to 30 days after last dose of study treatment for SAEs (up to 44 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Vital Sign Measurements</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Criteria for abnormalities in vital sign measurements: Diastolic blood pressure: Value &gt;90 and change from baseline &gt; 0 or value &lt; 55 and change from baseline &lt;-10. Systolic blood pressure: Value &gt;140 and change from baseline &gt;20 or value &lt;90 and change from baseline &lt;-20. Heart rate: Value &gt;100 and change from baseline &gt;30 or value &lt;55 and change from baseline &lt;-15. Respiration: Value &gt;16 or change from baseline &gt;10. Temperature: Value &gt;38.3°C or change from baseline &gt;1.6°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Abnormalities in ECG findings included: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, and second- or third-degree heart block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Abnormalities in Hematology Laboratory Test Results</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Criteria for marked abnormalities in test results: Platelet count &gt;1.5*upper limits of normal (ULN) value, &gt;1.5*ULN if pretreatment (PreRx) value is missing, &lt;0.85*lower limit of normal (LLN) if PreRx ≥LLN, &lt;0.85*LLN if PreRx is missing, &lt;0.85*PreRx if PreRx &lt;LLN. Leukocytes &gt;1.2*ULN if LLN ≤PreRx ≤ULN, &gt;1.2*ULN if PreRx is missing, &gt;1.5*PreRx if PreRx &gt;ULN, &gt;ULN if PreRx &lt;LLN, &lt;0.85*PreRx if PreRx &lt;LLN, &lt;0.9*LLN if LLN ≤PreRx ≤ULN, &lt;0.9*LLN if PreRx is missing and &lt;LLN if PreRx &gt;ULN. Lymphocytes &gt;7.5*10^3 c/uL and &lt;0.75*10^3 c/uL. Neutrophils &lt;0.85*PreRx if PreRx &lt;1.5*ULN, &lt;1.5*ULN if PreRx ≥1.5*ULN and &lt;1.5*ULN if PreRx is missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Urinalysis and Other Chemistry Testing Results</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Criteria for marked abnormalities on laboratory test results: urinary dipstick blood: ≥2 if pretreatment (PreRx) &lt;1, ≥2 if PreRx is missing or ≥2*PreRx if PreRx ≥1. Urinary microscopic red blood cell (RBC): ≥2 if PreRx &lt;2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Urinary microscopic white blood cell (WBC): ≥2 if PreRx &lt;2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Lactate dehydrogenase &gt;1.25*upper limit of normal (ULN) if PreRx ≤ULN, &gt;1.25*ULN if PreRx is missing and &gt;1.5*PreRx if PreRx &gt;ULN.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group 1: Daclatasvir and Darunavir/Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Daclatasvir oral tablet on specific days
Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Daclatasvir and Lopinavir/Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C: Daclatasvir oral tablet on specific days
Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <arm_group_label>Group 1: Daclatasvir and Darunavir/Ritonavir</arm_group_label>
    <arm_group_label>Group 2: Daclatasvir and Lopinavir/Ritonavir</arm_group_label>
    <other_name>BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <arm_group_label>Group 1: Daclatasvir and Darunavir/Ritonavir</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>Group 1: Daclatasvir and Darunavir/Ritonavir</arm_group_label>
    <arm_group_label>Group 2: Daclatasvir and Lopinavir/Ritonavir</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <arm_group_label>Group 2: Daclatasvir and Lopinavir/Ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Key Inclusion Criteria:

          -  Healthy male and female participants, aged 18 to 49, as determined by medical
             history, physical examination, 12 lead electrocardiogram, vital signs, and clinical
             laboratory evaluations

        Key Exclusion Criteria:

          -  Any significant acute or chronic medical illness; donation of blood to a blood bank
             or in a clinical study (except a screening visit) within 4 weeks of study drug
             administration (within 2 weeks for plasma only); or blood screen findings positive
             for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 and HIV-2 antibodies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries, Llc D/B/A Icon Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 29, 2015</lastchanged_date>
  <firstreceived_date>June 6, 2014</firstreceived_date>
  <firstreceived_results_date>August 21, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
